Tailoring the most desired therapy to each individual patient is the primary goal of precision medicine. A reliable and robust predictive model of drug effectiveness based on patients' unique genomic background is the key. For decades, communities have been trying to establish the relationship between molecular characteristics and drug response in complex diseases. Over the last decade, a large amount of genomic and epigenomic data together with pharmacogenomics data and response to perturbations data has been generated for many human cell lines through collaborations in the research community. These projects have led to significant therapeutic discoveries and have provided unprecedented opportunities to predict drug response using molecular fingerprints. However, even with great interest and effort in developing computational methods for predicting drug response, the prediction accuracies are at best only moderate. A related but distinct question is to understand the mechanisms of action (MOA) of drugs. Understanding drug MOAs enables characterization of drug side effects and identification of old drugs for new uses (i.e. drug repositioning). The traditional experimental assays to identify MOAs of drugs are expensive and time- consuming. There are three key questions to be addressed in the study. 1. Can novel computational approaches largely improve prediction accuracy of response to single drugs using comprehensive genomic and chemical information? 2. Can computational approaches provide a systematic way to mine genomics and drug response data to generate biological insights into the mechanisms of actions of various drugs? 3. Is it possible to develop an interpretable and accurate computation model to predict drug combination effects using pharmacogenomics data? Inherent features make it very challenging to predict drug response accurately: High-dimensionality of input data, the complex relationship between input features and response data; and heterogeneous drug/compound response patterns across different genetic lineages. Recently, artificial intelligence (AI) has been making remarkable strides in various applications owing to the rapid progress of ?deep learning.
In Aim 1 of this study, we will develop novel AI-based approaches to address the computational challenges of improving the prediction accuracy of drug response.
In Aim 2 of the study, we will develop a novel computation framework to study of MOA of drugs.
In Aim 3, we will develop an interpretable deep-learning based computational framework to predict drug combination effects. In addition, we will develop a user-friendly web portal as an integrated research platform to share the methodology, algorithms and data generated from this proposed study to the research community.

Public Health Relevance

Tailoring the most desired therapy to each individual patient is the primary goal of precision medicine. The proposed study aims to develop novel computational approaches to predict drug response and drug combination effects accurately.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Unknown (R35)
Project #
1R35GM136375-01
Application #
9931964
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Brazhnik, Paul
Project Start
2020-04-01
Project End
2025-03-31
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
1
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Other Clinical Sciences
Type
Schools of Medicine
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390